Gilead Sciences shares are trading lower after the company decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes due to futility based on a planned analysis.
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences has decided to discontinue its Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes due to futility based on a planned analysis. This has led to a decrease in the company's share price.
July 24, 2023 | 10:21 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Gilead Sciences' decision to discontinue its Phase 3 ENHANCE study has negatively impacted its share price.
The discontinuation of a major study often leads to a decrease in a company's share price as it indicates a setback in the company's product development. This is the case with Gilead Sciences, which has seen its share price drop following the announcement of the discontinuation of its Phase 3 ENHANCE study.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100